.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01ED05_Lorlatinib.Lorlatinib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01ED05_Lorlatinib.Lorlatinib| name: | Lorlatinib | |
| ATC code: | L01ED05 | route: | oral |
| compartments: | 2 | |
| dosage: | 100 | mg |
| volume of distribution: | 305 | L |
| clearance: | 8.6 | L/h |
| other parameters in model implementation | ||
Lorlatinib is a third-generation, reversible, macrocyclic tyrosine kinase inhibitor targeting anaplastic lymphoma kinase (ALK) and ROS1, approved for use in non-small cell lung cancer (NSCLC) patients with ALK-positive tumors, particularly after resistance to earlier-generation ALK inhibitors.
Pharmacokinetic parameters reported in adult patients with ALK-positive advanced NSCLC after oral administration under fasted conditions.
Damoiseaux, D, et al., & Dorlo, TPC (2022). Predictiveness of the Human-CYP3A4-Transgenic Mouse Model (Cyp3aXAV) for Human Drug Exposure of CYP3A4-Metabolized Drugs. Pharmaceuticals (Basel, Switzerland) 15(7) –. DOI:10.3390/ph15070860 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35890158